Antisense oligodeoxynucleotides targeted to bcr-ab1 are potential ex vivo purging agents for use with autologous bone marrow transplantation in the treatment of chronic myeloid leukemia (CML). We investigated, in a cell-free system, the activity and nuclease resistance of phosphodiester, phosphorothioate, chimeric methylphosphonate/phosphodiester, and chimeric methylphosphonate/phosphorothioate antisense octadecamers directed against either b2a2 or b3a2 bcr-ab1 breakpoint RNAs. Certain chimeric compounds were shown to possess targeted activity broadly equal to the parent phosphodiester or phosphorothioate forms and greater resistance to the nucleases present in cell extracts. Selected chimeric structures were compared with phosphodiester C HRONIC MYELOID LEUKEMIA (CML) is a serious neoplastic disorder of the hematopoietic stem cell in which the leukemic cells carry a specific chromosomal defect termed the Philadelphia (Ph) chromosome. The Ph chromosome is characterized by a translocation t(9; 22)(q34; q 1 1) that results in the fusion of c-ubl and the major breakpoint cluster region (bcr) genes.' Aberrant bcr-ubl transcripts derived from this region consist of a proximal bcr-derived portion, terminating with exon 2 (b2) or exon 3 (b3), linked to a distal c-ubi derivative, exons 2 to 1 1 (a2). The BCR-ABL (p210) tyrosine kinase displays enhanced activity over wild-type c-ABL (~145)' and is believed to play a central role in the pathogenesis of CML.
The effect of antisense compounds complementary to bcrabi breakpoint sequences on bcr-ubi mRNA abundance and CML cell proliferation has been investigated. The initial dramatic effects'".'' have not been broadly confirmed." Antisense oligodeoxynucleotides can decrease bcr-ubi transcript level and CML cell growth in ~u l t u r e , '~"~ although probably not to the degree required to restore Ph chromosome-negative hematopoiesis. 16 Clearly, if anti-bcr-ubi oligodeoxynucleotides are to be clinically relevant, there is a need to improve their potency and reduce toxic side effects. The precise chemistry of an antisense analogue's sugar-phosphate backbone can significantly affect its antisense properties. The widely used'"." phosphodiester oligodeoxynucleotides, which have the same structure as natural DNA, have been shown to be rapidly degraded by the nucleases found in biologic This nucleolytic digestion of the antisense effectors may lead to a lowering of drug concentration to half its original value over a period of only minutes to hours and to the release of toxic deoxynucleoside and deoxynucleotide monomers. Furthermore, phosphodiester effectors are potentially capable of producing nonspecific biologic effects by directing RNase H cleavage at sites in other RNA molecules that display only partial complementarity2" to the oligodeoxynucleotide. The comparatively nuclease-resistant phosphorothioate analogues" are also widely but have elsewhere been shown to induce sequence independent toxicity through interactions with protein^^*^^-'^ and may also direct RNase H activity at nontarget, partially complementary, RNA sequences. 26 Oligodeoxynucleotides that contain only methylphosphonate internucleoside linkages have been found to be nuclease resistantz7 but incapable of directing RNase H." Antisense effects observed with compounds of this structure cannot, therefore, be due to the RNase Hmediated RNA cleavage mechanism, in contrast to both phosphodiester and phosphorothioate structures. Furthermore, antisense effects against mRNA necessarily generated by physical obstruction of ribosome function may be expected to be particularly inefficient with methylphosphonate analogues because of their very low RNA hybrid stabilitie^.'^^^ This finding means that particularly high concentrations of such oligomers are required for sufficient target site occupancy to inhibit translation of the mRNA into protein.
We have previously shown that chimeric oligodeoxynucleotide analogues composed of terminal methylphosphonate regions surrounding a central core of phosphodiester residues possess the beneficial characteristics for antisense effectors of enhanced resistance to exonuclease^,'^ while retaining the capacity to direct RNase H?8s29 Furthemore, we have shown that chimeric methylphosphonate/phosphodiester oligodeoxynucleotide analogues induce RNase H-dependent antisense effects, both in vitro20. 26 and in vivo,3o with greater RNA target site selectivity than phosphodiester or phosphorothioate analogues and with similar, or greater, activity at the target site.
The foregoing considerations suggested to us that the antisense oligodeoxynucleotide structures previously used for targeting bcr-ab1 may have been suboptimal. Our aim in this investigation was to compare a series of oligodeoxynucleotides with varying internucleoside chemistries in terms of their ability to selectively and efficiently target b2a2 and b3a2 bcr-ab1 messenger RNA. First, a cell-free assay system was developed that used a human cell extract that contained RNase H activities and that was applied under conditions of physiologic ionic composition and temperature. Oligodeoxynucleotides composed entirely of phosphodiester internucleoside linkages or entirely of phosphorothiodiester residues were tested alongside chimeric methylphosphonate/ phosphodiester and the recently described chimeric methylphosphonate/phosphorothioate3' structures. We report that the chimeric molecules were far superior to the phosphodiester compounds in terms of stability to the nucleases present in the cell extract. In addition, certain of these structures directed RNase H in vitro with equal activity and much greater selectivity than did either the phosphodiester or phosphorothioate effectors, although some of the more highly methylphosphonate-modified compounds showed reduced activity. On the basis of the in vitro work, we extended our investigation to intact human cells. Human CML cells were "biochemically mi~roinjected"~~ with bcr-ab1 antisense phosphodiester, phosphorothioate, and the chimeric methylphosphonate/phosphudiester and methylphosphonatelphosphorothioate oligodeoxynucleotides that showed the greatest activity in vitro to test for their in vivo activity at reducing the level of bcr-ab1 messenger RNAs. Of the eight antisense effectors tested, all but one (chimeric methylphosphonate/ phosphorothioate, targeted to b3a2 mRNA) induced an antisense effect in vivo. We show that the order of activity in vivo was chimeric methylphosphonate/phosphodiester 2 phosphodiester > phosphorothioate > chimeric methylphosphonate/phosphorothioate.
MATERIALS AND METHODS
Oligodeoxynucleotide Synthesis and Purijcation Figure 1 shows the oligodeoxynucleotides used in this study. Phosphodiester and chimeric methylphosphonatdphosphodiester oligodeoxynucleotides were synthesized as previously reported' using phosphoramidites and methyiphosphonamidites from Glen Research Inc (UK Supplier, Cambio, Cambridge, UK) and the slow 1 pmol cycle (version 1.23) on an Applied Biosystems (Warrington, Cheshire, UK) 381A DNA synthesizer, with the exception that the base deprotection procedure recommended by Agrawal and G~o d c h i l d~~ was substituted for that used by Miller et al." In our hands, the former short treatment with concentrated ammonia solution at room temperature before ethylenediamine/ethanol deprotection gave a much cleaner product than hydrazine hydrate, in which substantial base modification was observed. When Aminolink 2 (Applied Biosystems) was incorporated at the 5' end of the oligodeoxynucleotide as the final cycle of synthesis for subsequent attachment of fluorescein, the ammonia treatment was extended from 2 hours to 4 hours to ensure complete deprotection of the linker amino group. In every case treatment with ethylenediamine/ethanol (1 : 1 by volume) was for 18 hours.
Oligodeoxynucleotide phosphorothioates and chimeric methylphosphonate/phosphorothioates were synthesized in like manner using the Applied Biosystems 1 pmol phosphorothioate cycle (User Bulletin No. 58) and tetraethylthiuram disulphide (TETD) as the sulphurizing reagent in place of the iodine oxidizing reagent on the synthesi~er.~~ Phosphorothioates were purified by ion exchange high performance liquid chromatography (HPLC) on an MA7 Plasmid column (BioRad, Hemel Hempstead, Hertfordshire, UK) to separate the desired products from oligomers containing failed sulphurization, phosphodiester linkages, which are not removed by reverse-phase purification strategies, as described by Zon."
Cell Culture
The acute lymphoblastic leukemia MOLT4 (European Collection of Animal Cell Cultures [ECACC] , Porton Down, Wiltshire, UK) and chronic myeloid leukemia cell lines K562 (ECACC), KYOI, and LAMA84 (generous gifts of Drs M. Kirkland and S . O'Brien, L W Leukaemia Unit, Hammersmith Hospital, London, UK) were maintained in exponential growth in RPM1 1640 medium (GIBCO, Paisley, Renfrewshire, UK) supplemented with 10% heat-inactivated (65°C for 1 hour) fetal calf serum (Sera-Lab, Crawley Down, Sussex, UK). All procedures were performed on cultures assayed to be greater than 95% viable by trypan blue exclusion.
Preparation of bcr-ab1 In Vitro Transcripts Total RNA was purified by a guanidine thiocyanatdacid phenol method36 from KYOl and K562 cell lines. Reverse transcription (RT) reactions were performed on 5 pg samples of RNA in 50 pL reactions using 20 U/pL superscript reverse transcriptase (GIBCO) and 3.3 pmol/L random nonamers. Reactions were terminated by incubation at 90°C for 5 minutes. One-hundred-microliter "hotstart" polymerase chain reactions (PCRs) were performed by assem- 
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Human bcr-ab/ oligodeoxynucleotide structures and sequences. A dash (-) between bases indicates the presence of a normal phosphodiester linkage, whereas a slash ( I ) indicates a methylphosphonate internucleoside linkage and an asterisk (*) indicates a phosphorothioate linkage. Fluorescein attachment to the 5' and 3' termini via a 6-amino-l-hexanol-linker is indicated by -F and F-, respectively. The name of each oligodeoxynucleotide is shown to the right of the sequence and is derived from the structure and sequence as below. The series is shown by the first two alphanumerics "26 or "38". indicating b2a2 and b3e2 break point targets, respectively. The next three or four alphanumerics indicate structure in the conventional 5' to 3' direction: "17p" has all internucleoside bonds of the normal phosphodiester type, "494" has four methylphosphonates at both termini and nine central phosphodiesters, "65s6 has six methylphosphonates at each end and five central phorphorothioatw, and "17s" has all internucleoside linkages of the phosphorothioate type. The next two characters indicate actual sequence, " A S being antisense. Finally, "5'F-" and "-3'"' denote fluorescein attachment to the 5' and 3' termini, respectively.
to position 274 to 253 of accession no. X16416) 5' . . . Dig-TCA GAC CCT GAG GCT CAA AGT C . . . 3 ' .
Transcripts containing low levels of digoxigenin label were obtained as previously described" using l7 RNA polymerase (Epicenter, UK Distributors Cambio). The RNAs were purified from template DNA and contaminating PCR primers, as described above for total RNA,36 and ethanol precipitated using linear polyacrylamide as B3a2 transcripts were 434nt long, containing 152nt bcr and 282nt c-abl, whereas b2a2 transcripts were 359nt long, containing 77nt bcr and 282nt c-abl.
Preparation of Human Cell Extract
Whole cell extract was obtained from the MOLT4 acute lymphoblastic leukemia cell line using the ammonium sulphate fractionation technique described by M a n l e~.~~ Small aliquots (100 pL) of the dialyzed final solution were stored in liquid nitrogen and could be thawed on i c e h a p frozen at least three times before significant reduction of RNase H activity was evident.
Cell Extract Assays
Assays were conducted with 50 to 100 ng of digoxigenin-labeled transcript per 10 pL of reaction at 37°C in an intracellular buffer (1 I mmoVL potassium phosphate, pH 7.4, 108 mmoVL KC1, 22 mmoVL NaCI, 1 mmol/L dithiothreitol, 3 mmoVL MgCI2, 1 mmol/L ATP) with 1 pmolfl, oligodeoxynucleotide, I U/pL human placental ribonuclease inhibitor (Stratagene) and 1 pg/pL yeast tRNA. Whole cell extract was added to 10% of the final reaction volume. Membranes were placed to dry at 50°C and subsequently UV crosslinked ( h = 254 nm, 2 minutes). Digoxigenin-labeled RNAs were detected using alkaline phosphatase-conjugated antidigoxigenin Fab fragments (Boehringer, Lewes, East Sussex, UK) and the chemiluminescent protocol recommended by the suppliers of the chemiluminescent substrate CSPD (Tropix, UK Suppliers Cambridge Bioscience, Cambridge, UK). Autoradiographs were scanned densitometrically using a Shimadzu CS9000 Flying Spot instrument (UK suppliers, VA Howe & CO Ltd. Banbury, Oxfordshire, UK).
Oligodeoxynucleotide analysis. Samples (2 pL) were removed to 10 pL ice-cold 10 mmoVL EDTA (pH 8.0). For polyacrylamide gel electrophoresis (PAGE) analysis, 3 pL aliquots (0.5 pmol oligodeoxynucleotide) were mixed with 7 pL gel loading buffer (vide supra) treated as for RNA and fractionated by an identical electrophoretic procedure, except that the gels used were 15% polyacrylamide (rather than 6%). Nucleic acids contained in the gel were electroblotted onto Nytran NY12N membrane, as described above. Inspection of the dried membrane under UV illumination showed fluorescent compounds on the membrane surface. Detection of fluorescein-labeled oligodeoxynucleotides and degradation products UV crosslinked to the membrane (X = 254 nm, 3 minutes) could be enhanced using an W i n e phosphatase-conjugated antifluorescein Fab fragment (Boehringer) and the chemiluminescent CSPD protocol, as for digoxigenin-labeled RNA. Phosphorothioate and chimeric methylphosphonatdphosphorothioate oligodeoxynucleotides produced very poor chemiluminescent signals compared with analogous phosphodiester compounds, despite showing no greater tendency to elute from the membrane during processing. For HPLC analysis, oligodeoxynucleotides containing six or more phosphodiester or phosphorothioate residues were analyzed by weak anion exchange chromatography (MA7 plasmid column held at 65°C; BioRad) with a gradient of 0 to 1.5 m o m KC1 in 20 mmol/L potassium phosphatebuffered 50% formamide, pH 7.5, over 60 minutes at a flow rate of 1 W m i n . Oligodeoxynucleotide analogues with fewer charges were analyzed by reverse-phase chromatography (Asahipak Shodex C8P-50 column; Asahi Chemical Industry CO Ltd, UK Suppliers Prolabo, Manchester, UK) with a gradient of 5% to 50% acetonitrild0.1 mol/ L triethylammonium acetate (TEAA), pH 8.0, over 20 minutes at a flow rate of 1 W m i n . Aliquots (6 pL) of the oligodeoxynucleotide-EDTA solution (l pm01 oligomer) were diluted to 100 pL with the appropriate weak buffer, heated to 95°C for 5 minutes, and immediately injected onto the column. Fluorescent compounds in the column effluents were detected with a 1046A Programmable Fluorescence Detector (Hewlett Packard, UK Suppliers Anachem, Luton, Bedfordshire, UK) with excitation and emission gratings set to 494 and 530 nm, respectively.
Reversible Cell Peneabilization With Streptolysin 0
KYOl and LAMA84 cells were treated with streptolysin 0 essentially according to the protocol of Barry et a139 as modified by Spiller and Tidd?' Briefly, IO6 cells were washed in permeabilization buffer (137 mmolR. NaC1, 100 mmoVL PIPES, pH 7.4, 5.6 mmoVL glucose, 2.7 mmoVL KCl, 2.7 mmoVL EGTA, 1 mmoVL ATP, 0.1% bovine semm albumin) and resuspended in 100 pL of preactivated (5 dithiothreitol, 1 mmoVL ATP, overnight) streptolysin 0 solution (Sigma Chemical CO, Poole, Dorset, UK) in permeabilization buffer containing 0 or 20 pmoVL antisense oligodeoxynucleotide and incubated at 37°C for 20 minutes. Resealing was achieved by the addition of 1 mL RPM1 1640 medium containing 10% fetal calf serum and incubation was continued at 37°C for a further 220 minutes before RNA extraction. All experiments were performed with duplicates for each oligodeoxynucleotide treatment and no oligodeoxynucleotide control points. RNA was purified from experimental cell cultures using a guanidine thiocyanate/acid phenol method.36 RNA precipitates were resuspended in water and their concentration was estimated by gel electrophoresis and ethidium bromide staining.
Semiquantitative RT-PCR (SQRT-PCR)
RNA (approximately 1 pg) was suspended in 4 pL ddH20, heated to 80°C for 5 minutes, and then placed at 37°C for 5 minutes. Ribonuclease Inhibitor (40 U; Stratagene) and the RT primer (2 pmol) were added in native Pfu polymerase PCR buffer, dithiothreito1 solution (final concentrations 1 X and 10 mmoVL, respectively), and incubation continued at 37°C for 45 minutes. At the end of this period, 200 U superscript reverse transcriptase (GIBCO) and dNTPs (final concentration, 500 pmoVL each) were added in I X PCR buffer, 10 mmoVL dithiothreitol (final reaction volume, 10 pL) and incubation was extended for a further 45 minutes at 37°C. Reactions were stopped by heating to 95°C for 5 minutes followed by treatment with 1 ng RNase A (type III-A; Sigma) for 20 minutes at 37°C before PCR amplification. For PCR1, 10 pL 1X PCR buffer containing 20 pm01 of each primer and 0.5 U of native Pfu polymerase was added to the inactivated RT reaction and overlaid with mineral oil before thermal cycling. For PCR2, 5 p L was taken from PCRl reactions and added to 15 pL 1 X PCR buffer containing 15 pmol sense primer, 20 pm01 digoxigenin-tagged antisense primer, 0.5 U Pfu polymerase, and 3 nmoI of each dNTP. Reactions were overlaid with mineral oil before subamplification. Semiquantitation was achieved by limiting the first PCR round to 15 cycles and the second PCR to 5 cycles. We have found the signal to be linear with input RNA over the range of IO ng to 1 pg using this protocol (data not shown). Reverse transcription and PCR primers were as follows: reverse transcription primer, 5' TGT TGA CTG GCG TGA TGT AGT TGC 'IT 3'; sense primer, 5' GGT ACC TAA TAC GAC TCA CTA TAG GGA GAA GCT TGG AGC TGC AGA TGC TGA CCA AC 3'; PCRl antisense primer, 5' AGA GAG GGA TCC AAC GAG CGG CTT CAC TCA G 3'; nested-labeled PCR2 antisense primer, 5' digoxigenin-TCA GAC CCT GAG GCT CAA AGT C 3'. Final analysis of SQRT-PCR products was accomplished by electrophoresis through 0.75-mm thick 6% polyacrylamide sequencing gels, semidry electrotransfer (Trans-Blot; BioRad) onto Nytran NY12N membrane, and detection by antidigoxigenin-alkaline phosphatase Fab fragments with a chromogenic procedure. The resultant blots were scanned densitometrically as previously describedm and each data point was normalized to the mean of the duplicate "No Oligo" control values. The statistical significance of the results was calculated using singlevariable ANOVA, as below.
Computational Methods
The Sun network based Wisconsin GCG package was used for sequence analysis and manipulation. Sequences were obtained from Genbank using the "Fetch" program and manipulated to produce the required fragments via "Bestfit" and "Seqed." RNA secondary structures were calculated using the "FoldRNA" routine and graphical display obtained by piping this output into the "Squiggles" program. Single variable ANOVA was performed using the MICRO-TAB program running on an Archimedes 440. 
Oligodeoxynucleotide

RESULTS AND DISCUSSION
To delineate the intracellular effects that might pertain during future bcr-ab1 antisense bone marrow purging experiments, we have looked at the interactions of oligodeoxynucleotides, bcr-ab1 RNA, and human ribonuclease H (RNase H) initially in cell-free systems under physiologic conditions.
The In Vitro Test System
All of the oligodeoxynucleotides and analogue structures used in these experiments were fluorescein labeled at either the 5' or 3' termini, as depicted in Fig 1. The cell extracts containing RNase H enzymes were obtained from the human acute lymphoblastic leukemia cell line MOLT4 by a previously described procedure.'8 The RNase H activity in these crude cell extracts had a limited lifetime under the assay conditions, presumably because of progressive proteolytic destruction of the enzyme molecules. Consequently, the bars in, eg, Fig 2 represent total cleavage occurring before enzyme decay. The bcr-ab1 target RNAs for these experiments were obtained by in vitro transcription of cDNA fragments derived from bcr-abl mRNAs by RT-PCR, as described in the Materials and Methods. The in vitro transcript RNA molecules were of different lengths depending on breakpoint type: b3a2 transcripts were 434nt long and b2a2 transcripts were 359nt long (data not shown).
Methylphosphonate/Phosphodiester Chimeric Analogues Can Be Eficient and Specific Antisense Esfectors In Vitro
The ability of the antisense oligodeoxynucleotides to direct crude human RNase H activities to cleave 359nt b2a2 or 434nt b3a2 bcr-ab1 in vitro transcribed RNA was examined. Phosphorothioate ( I~s ) , phosphodiester (17p), and the range of chimeric methylphosphonate/phosphodiester oligodeoxynucleotide structures complementary to either the b2a2 or b3a2 sequences were studied (structures, sequences, and names as shown in Fig 1) . The results of a representative experiment are presented in Fig 2. Oligodeoxynucleotide- and either 152nt (bcr, b3) or 77nt (bcr, b2) depending on the target RNA sequence. Substrate and product RNA fragments were fractionated by electrophoresis and imaged by chemiluminescence and the extent of cleavage quantitated by densitometry. The 17s, 17p, and chimeric 494 (chimeric with 4 methylphosphonates at each end and 9 central phosphodiesters) b3a2 antisense oligodeoxynucleotides induced broadly equivalent levels of cleavage at the target site on b3a2 RNA (40% to 55%). Rather less target scission (10% to 15%) was observed with the chimeric 3B656 structure (6 methylphosphonates at each termini, 5 central phosphodiester residues), indicating that, for this RNA target at least, the 656 structure may be expected to be an inefficient antisense effector. In contrast, the b2a2 RNA was efficiently cleaved (85%) at the target site by the b2a2 antisense sequence 656 chimeric oligodeoxynucleotide. Indeed, the extent of cleavage was not substantially different from that obtained (90% to 95%) with the homologous 494. 17p, and 17s compounds. At no time was either b2a2 or b3a2 RNA cleaved by human RNase H in the presence of chimeric 737 antisense oligomers (7 methylphosphonates at each end, 3 central phosphodiesters). This finding would appear to reflect a property of the human enzymes because in previous experiments 737 structure anti-bcr-ab1 effectors were shown to be capable of directing Escherichia coli RNase H to cut bcr-ab1 RNA targets (data not shown).
The results presented in Fig 2 show that both phosphodiester and phosphorothioate oligodeoxynucleotides can promote undesired activity of human RNase H in vitro because both structures directed cleavage of nontarget sequence bcr-ab1 RNAs. Much higher selectivity of RNA scission was observed with the chimeric methylphosphonate/phosphodiester bcr-abl antisense effectors. Not one of the chimeric structures, of either sequence, induced detectable nontargeted enzyme activity. In contrast, b2a2 RNA was digested by RNase H in the presence of 3B17pAS-3'F and 3B17sAS-3'F antisense oligodeoxynucleotides (to produce fragments consis-tively) may be explained by the differing secondary structures of their target sites and by the low RNA hybridization potential of oligodeoxynucleotides with high methylphosphonate content?*' which limits their capacity to invade stable RNA duplexes. tent with cleavage at the b2a2 breakpoint; data not shown) and b3a2 RNA was cut by RNase H in the presence of the 2B 17pAS-3'F oligodeoxynucleotide (to produce fragments consistent with some cleavage at the b3a2 breakpoint, but mostly at the junction between bcr exons b2 and b3; data not shown). It would thus appear that inappropriate cleavage by human RNase H enzymes can occur, under physiologic conditions, at regions of partial complementarity between RNA and oligodeoxynucleotides, as previously reported for E. coli RNase H.20.26
Antisense EfJiciency May Be Limited by Target RNA Secondary Structure
One of the most striking aspects of the results presented in Fig 2 is the substantial difference in maximal extent of cleavage of b2a2 and b3a2 RNAs, ie, 95% b2a2 RNA (SF-2B494AS) versus 55% b3a2 RNA (3B17pAS-3'F). which may reflect differences in target site accessibility. The calculated secondary structures of the 434nt b3a2 and 359nt b2a2 in vitro transcripts are presented in Fig 3. It may be seen that the b3a2 breakpoint resides within a stable stem structure, whereas the b2a2 breakpoint is in an open loop region and may therefore be rather more accessible for hybridization to oligodeoxynucleotides. The even more significant difference in targeted activity obtained with 5'F-2B656AS and 5'F-3B656AS oligodeoxynucleotides (85% and 15%, respec-
Methylphosphonate/Phosphodiester Chimeric Analogues Are More Nuclease-Resistant Than Phosphodiester Compounds
The stability of the oligodeoxynucleotides and analogues in cell extract was investigated, and the data are presented in Fig 4. Both of the 17p structures, previously reported"." to be effective antisense agents in the treatment of cells over periods of days to weeks, can be seen to be highly unstable, with the b3a2 antisense oligodeoxynucleotide digested to completion within 30 minutes and the b2a2 antisense oligodeoxynucleotide more than 50% degraded after exposure for the same time. Such sequence dependent difference in nuclease sensitivity has been previously reported:' Furthermore, it should be noted that the 3' linkage of fluorescein to the phosphodiester oligodeoxynucleotides used in this study bestows resistance to 3'-5' exonucleases (Tidd and Spiller, unpublished results), the major nuclease component of biologic fluids.l7*IR Therefore, enzymatic digestion of these particular phosphodiester oligodeoxynucleotides proceeds via an initial, rate-limiting endonucleolytic attack, which is consistent with the HPLC traces presented.
In contrast, chimeric methylphosphonate/phosphodiester oligodeoxynucleotides were comparatively stable to the nucleases found in cell extracts, with the 5'F-3B494AS compound less than 20% degraded after 30 minutes and the 5'F-2B656AS less than 5% digested over the same period. Essentially equivalent results were obtained for 5'F-2B494AS and SF-3B656AS oligodeoxynucleotides, respectively (data not shown). Reverse-phase HPLC and polyacrylamide gel electrophoresis indicated that both 737 structure chimeric analogues remained undegraded over the assay period (data not shown). The reduced sensitivity of chimeric methylphosphonodiester/phosphodiester oligodeoxynucleotides to cellular endonucleases with increased methylphosphonate substitution of phosphodiester internucleoside linkages is in agreement with previously published data obtained with purified nucleases.27
The 3'-fluorescein-labeled 17s phosphorothioate oligodeoxynucleotides were also found to be completely stable for at least 30 minutes of incubation with the cell extract (data not shown).
Methylphosphonate/Phosphorothioate Chimeric Analogues Are ESJicient and Specijic In Vitro and Are Nuclease-Resistant
It appeared that efficient antisense activity against b3a2 RNA (Fig 2) required the oligodeoxynucleotide to possess more than five central phosphodiester residues, presumably to be able to invade the stable stem structure at the target site, (Fig 3) and yet chimeric 494 methylphosphonatelphosphodiesters were not completely stable to nucleases (Fig 4) . We therefore decided to replace the nuclease labile phosphodiester linkages within the chimeric structures with relatively T" J wa stable phosphorothioate internucleoside bonds to produce the recently described3' methylphosphonate/phosphorothioate chimeric analogues. The b3a2 antisense compounds, 3B49s4AS-3'F (4 methylphosphonates at each end, 9 central phosphorothioate residues), 3B65s6AS-3'F, and 3B73s7AS-3'F, were all found to be completely stable to the cell extract nucleases over the assay period when analyzed by PAGE (data not shown) and weak anion exchange €"LC (49s4 and 65s6 only; Fig 4) .
The range of b3a2 antisense phosphorothioate and methylphosphonate/phosphorothioate oligodeoxynucleotides were tested for activity at directing human RNase H cleavage of target b3a2 and nontarget b2a2 RNAs, and the results are presented in Fig 5. It may be seen that the all-phosphorothioate analogue induced approximately 60% cleavage of b3a2 target, but also approximately 30% of b2a2 RNA was inappropriately digested, which is consistent with the previous observations (Fig 2) . The chimeric methylphosphonate/phosphorothioate oligodeoxynucleotide 3B49s4AS-3'F induced approximately 45% cleavage of b3a2 RNA, a level of activ- ity similar to that displayed by the congenic methylphosphonate/phosphodiester compound, and displayed no apparent cross-reactivity with b2a2 RNA. No cleavage of b3a2 RNA was detectable in assays containing 3B6%6AS-3'F, which may reflect even lower ability than 5'F-3B656AS to invade the target RNA secondary structure. The phosphorothioate modification is moderately helix destabilizing*' and replacement of the phosphodiester section in methylphosphonate/ phosphodiester chimeric oligodeoxynucleotides with phosphorothioates would be expected to result in further reduction of hybridization potential. The 73s7 structure proved to be inactive at directing human RNase H, as expected.
Antisense Oligodeoxynucleotide Activity In Vivo
It is evident that the most clinically relevant antisense effects are those that pertain within living cells. A procedure was developed that allowed in vivo antisense effects to be obtained and quantified. We have previously shown that reversible cell permeabiiization with streptolysin 0 is a relatively nontoxic method that efficiently introduces oligodeoxynucleotides into cells3* and that eels loaded with antisense effectors in this way readily show RNase H-dependent antisense effects!."
Human chronic myeloid leukemia KYOl (express b2a2 breakpoint bcr-ab1 mRNA) and LAMA84 (express b3a2 breakpoint bcr-ab1 mRNA) cells were biochemically microinjected with antisense oligodeoxynucleotides, using streptolysin 0.32 The effect on bcr-ab1 mRNA level 4 hours after introduction of the antisense effectors was analyzed by SQRT-PCR. The results presented in Fig 6 show the in vivo activity of bcr-abl18-mer b2a2 and b3a2 antisense, chimeric methylphosphonate/phosphodiester 494, chimeric methylphosphonate/phosphorothioate 4 9~4 , and all-phosphodiester and all-phosphorothioate oligodeoxynucleotides (Fig 1) . The histograms show mean bcr-ab1 mRNA level (as analyzed by SQRT-PCR) 2 the standard error (12 data points for each bar) relative to the "No Oligo" control cells. The graph was compiled from the results of three separate antisense experiments (for both the KYOl and LAMA84 cell lines); all experiments contained duplicates of each oligodeoxynucleotide and "No Oligo" (control) treatments; and the level of bcr-ab1 mRNA, in the total RNA prepared from every cellular treatment, was measured by two independent SQRT-PCRs. The intensities of the SQRT-PCR signals on each blot were determined by densitometry and each point was normalized to the mean of the duplicate "No Oligo" values on that blot, thus permitting comparison between the separate analyses and experiments.
In addition to the two different bcr-ab2 antisense sequences acting as controls for each other in these experiments, extensive control experiments have been previously performed and the data obtained were included in an earlier report.' The bcr-ab1 oligodeoxynucleotides were shown to be specific for bcr-ab1 mRNA in vivo. Under conditions that permitted efficient antisense b2a2 oligodeoxynucleotidemediated, RNase H-dependent scission of b2a2 bcr-ab1 mRNA in streptolysin 0-permeabilized KYOl cells, no variation in the level of either c-myc or p53 nontarget mRNAs was induced by either b2a2 or b3a2 antisense effectors. Furthermore, suppression of b2a2 bcr-abl mRNA in KYOl cells was selective to b2a2 antisense oligodeoxynucleotides. Both c-myc and p53 antisense oligodeoxynucleotides caused a substantial reduction in the level of their respective target mRNAs when biochemically microinjected into KYOl cells but no effect on bcr-ab1 mRNA level was observed in either case.
All four b2a2 antisense structures were effective at reducing b2a2 bcr-abl mRNA expression within KYOl cells, as shown in Fig 6A. Of these four oligodeoxynucleotides, it is evident that 5IF-2B494AS was the most active antisense effector, reducing the level of bcr-ab1 mRNA to around 5% of that in the "No 0ligo"-treated controls and that the chimeric methylphosphonate/phosphorothioate analogue (2B49s4AS-3'F) was the least effective (mRNA level approximately 33% of control), a difference that was statistically significant at the 0.1% level. The 17p and 17s structures may be seen to possess intermediate activities, with the phosphorothioate analogue somewhat less active than the phosphodiester oligodeoxynucleotide. Not one of the b3a2 targeted oligodeoxynucleotides induced a substantial reduction in b2a2 bcr-ab1 mRNA expression in KYOl cells (none different from the "No Oligo" control at the 1% level of significance).
On the other hand, as can be seen from Fig 6B, not one of the b2a2 antisense oligodeoxynucleotides reduced the expression of b3a2 bcr-ab1 mRNA in LAMA84 cells by any significant extent. B3a2 bcr-ab1 mRNA level was substantially lowered in LAMA84 cells treated with the 3B17pAS-3'F and 5'F-3B494AS (to approximately 30% of the "No Oligo" control level). The b3a2-targeted all-phosphorothioate antisense effector was significantly (P 1%) less effective than the homologous all-phosphodiester and chimeric 494 compounds at reducing the level of target bcr-ab1 mRNA (approximately 59% of the "No Oligo" control level). The chimeric methylphosphonate/phosphorothioate b3a2 oligodeoxynucleotide (3B49s4AS-3'F) was inactive as an antisense agent in that it induced no statistically significant reduction in the level of its target b3a2 bcr-ab1 mRNA when introduced into LAMA84 cells.
It is evident from comparing Fig 6A and B that the antisense effects obtained in the two different cell lines were not equally efficient. For example, the best antisense effect obtained in LAMA84 cells (with 3B17pAS-3'F and 5'F-3B494AS) was a reduction of bcr-ab1 mRNA level to around 30% of the "No Oligo" control, whereas the least efficient b2a2 antisense effector (2B49s4AS-3'F) caused a reduction of mRNA level in KYOl cells to approximately 33% of control. Such data are consistent with the in vitro results (Fig 2) that indicated that the b3a2 sequence was "difficult" and that b2a2 RNA sequence was "easy" to target for antisense effects, and so would be consistent with the full-length mRNAs possessing secondary structures in the region of the breakpoints, similar to those calculated for their respective in vitro transcripts (Fig 3) .
Overall, it appears clear that the oligodeoxynucleotide structures may be ranked for their ability to reduce the expression of bcr-ab1 mRNA in vivo 4 hours after introduction into the human KYOl (Fig 6A) and LAMA84 (Fig 6B) cells as chimeric methylphosphonate/phosphodiester 2 phosphodiester > phosphorothioate > chimeric methylphosphonate/ phosphorothioate. We have previously reported that phosphorothioate oligodeoxynucleotides can show reduced in vivo antisense activity compared with phosphodiester and chimeric methylphosphonate/phosphodiester effectors," a finding supported by the data of Fig 6. It is not clear precisely why this occurs, although it may be related to the tendency of phosphorothioate oligodeoxynucleotides to bind nonspecifically to proteins$22-25 which would be expected to reduce their solution concentrations and which also results in direct inhibition of human RNases H.25 Chimeric methylphosphonate/phosphorothioate oligodeoxynucleotides, in addition, may be expected to have reduced ability to invade RNA duplexes, because of the reduced RNA hybridization potential of antisense analogues that contain methylphosphonate internucleoside linkage^.^.'^ The inactivity of the antisense reagent 3B49s4AS-3'F at reducing the level of b3a2 bcrab1 mRNA in LAMA84 cells may, therefore, result from a combination of (1) "difficult" target RNA secondary structure, (2) low ability of the oligodeoxynucleotide to invade RNA secondary structure, (3) low solution concentration of the effector, and (4) direct inhibition of endogenous RNase H. In contrast, the comparatively nuclease-sensitive phosphodiester and chimeric methylphosphonate/phosphodiester oligodeoxynucleotides were found to be the most active antisense structures in vivo. The chimeric methylphosphonate/ phosphodiester 494 compound was more active than the homologous phosphodiester structure at reducing the expression of the accessible (Fig 3) b2a2 mRNA, 4 hours after treating the cells. We suggest that the 5'F-2B494AS structures moderately reduced ability to invade RNA secondary structures relative to 2B17pAS-3'F (resulting from its reduced RNA hybrid ~tability~.'~) was more than compensated by its substantially increased resistance to nucleases (Fig 4 and Tidd and Warenius"), permitting greater overall activity.
Conclusions
The data presented here are consistent with the view that target secondary structure (Fig 3) can significantly influence the overall level of antisense effect achieved, both in vitro (Figs 2 and 5) and in vivo (Fig 6) . The b3a2 breakpoint type mRNA appears to be a more difficult target than the b2a2 breakpoint mRNA. The best reduction in b3a2 bcr-ab/ mRNA level achieved in vivo was to approximately 30% of the "No Oligo" control (Fig 6 ) compared with approximately 5% with b2a2 mRNA. Greater activity at such recalcitrant targets might be obtained using oligodeoxynucleotide analogue structures that generate enhanced heteroduplex stability, such as 2'-O-methyl/phosphodiester chimeric molec u l e~~' or oligodeoxynucleotide analogues with 5-propynemodified pyrimidine bases.42A3 However, it is not clear what degree of selectivity would be obtained in vivo with these analogues that bind to RNA very tightly. The in vitro data presented here (Figs 2 and 5 ) and elsewhere20.z6 show that nontargeted activation of RNase H can correlate with increased RNA heteroduplex stability. On the other hand, it appears quite clear that living human cells are more stringent than our in vitro human cell extract system (compare Figs 2 and 6), perhaps due to RNAs being masked by protein to a greater extent in vivo. No significant undesired antisense effect was observed with any of the oligodeoxynucleotides tested either in KYOl or LAMA84 cells (Fig 6) .
Of the oligodeoxynucleotides tested, we conclude that the chimeric 494 methylphosphonate/phosphodiester analogues represent the optimum structure type for targeting bcr-abl mRNA in vivo. More highly methylphosphonate-modified compounds (eg, 656s) can show reduced activity in vitro (Fig 2) and so may be expected to be inefficient in vivo. Phosphorothioate and chimeric methylphosphonate/phosphorothioate" antisense effectors were shown to be significantly less active in vivo than chimeric methylphosphonate/ phosphodiester oligodeoxynucleotides (Fig 6) , particularly against b3a2 breakpoint mRNA. Indeed, when LAMA84 cells were treated with 3B17sAS-3'F, the level of bcr-ab1 mRNA remained at nearly 60% of that in the control cells (which were streptolysin 0 treated in the absence of oligodeoxynucleotide) 4 hours after they were loaded with large quantities of 3B 17sAS-3'F. In contrast, the phosphodiester oligodeoxynucleotides were found to be effective at reducing the level of bcr-ab/ mRNA in the short term (Fig 6) , but have been generally d i~c o u n t e d~,~"~ as potential antisense effectors for long-term treatments in vivo because of their sensitivity to nucleases (Fig 4 and Tidd and Warenius,I7 Abramova et al," and Hoke et all'). Data recently obtained with antisense effectors biochemically microinjected into CML cells showed that phosphodiester oligodeoxynucleotides were more rapidly degraded by nucleases than chimeric methylphosphonate/phosphodiester analogues in vivo. The 3' end-protected b2a2 antisense phosphodiester oligodeoxynucleotide (2B17pAS-3'F) possessed an in vivo half life (tl,Z) conservatively calculated at 30 minutes, whereas the chimeric congener S'F-2B494AS displayed a tllz of approximately 2 hours (data not shown). In addition, it was found that the anti-b3a2 phosphodiester oligodeoxynucleotide (3B 17pAS-3'F) was degraded substantially more rapidly than the equivalent anti-b2a2 structure in vivo (data not shown), as was also noticed in vitro (Fig 4) . Chimeric methylphosphonate/phosphodiester antisense effectors show the optimum combination of activity and resistance to nucleases for targeting bcr-ab1 mRNA in vivo of the compounds tested here.
This work is part of a critical evaluation of the therapeutic potential of antisense oligodeoxynucleotide analogues as ex vivo purging agents in the treatment of CML. On the basis of the results presented, we strongly suggest that the chimeric compounds described above possess antisense characteristics superior to those of analogues previously investigated for this purpose. However, it is not clear whether any oligodeoxynucleotide or analogue structure yet devised can achieve pharmacologically relevant intracellular concentrations without nonphysiologic manipulation of the cells. The uptake of antisense oligodeoxynucleotides into primary human leukaemia cells has been investigated (Broughton et al, manuscript submitted) and was found to be as inefficient as was previously reported for human leukemia cell lines7; in both cases a vesicular localization of oligodeoxynucleotide was observed. We have not obtained antisense effects in vivo with any of the compounds described in this report without using streptolysin 0 to biochemically microinject them into the cells. This finding is in line with an increasing number of reports stating that special steps need to be taken to introduce oligodeoxynucleotides into a cells cytoplasm before reliable antisense effects may be achieved:'-% We are currently investigating oligodeoxynucleotide modifications that may permit cytoplasmic and nuclear loadings to be obtained without such special treatment of the cells.
